β-catenin/CBP-IN-1

Cas：1198780-38-9

Product Information：

β-catenin/CBP-IN-1 is a potent and selective CBP/β-catenin antagonist, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus.

IC50 & Target: Wnt

Molecular Weight: 658.64

Formula: C₃₃H₃₅N₆O₇P

Smiles:

O=C(N(C([C@H](C)N1CC2=C3N=CC=CC3=CC=C2)N4[C@@H](CC5=CC=C(OP(O)(O)=O)C=C5)C1=O)N(C)CC4=O)NCC6=CC=CC=C6

Shipping:

Room temperature in continental US; may vary elsewhere.

Storage:

Powder    -20°C  3 years

4°C  2 years

In solvent -80°C  6 months

-20°C  1 month

In Vivo:

β-catenin/CBP-IN-1 (intraperitoneal injection;1mg/kg; 42 days) has a treatment effect on liver fibrosis in hepatic fibrosis Cre/loxP/HCV-MxCreTg mouse model.

References:

1. Takenao Odagami, et al. Prevention or treatment agent for hepatic fibrosis. Patent WO2014092154A1.

Products are for research use only. Not for human use.